It was investigated whether pharmacogenetic factors, both as single polymorphism and as gene--gene interactions, have an added value over non-genetic factors in predicting statin response. Five common polymorphisms were selected in apolipoprotein E, angiotensin-converting enzyme, hepatic lipase and toll-like receptor 4. Linear regression models were built and compared on R 2 to estimate the added value of single polymorphisms and gene-gene interactions. The selected polymorphisms and the gene--gene interactions had a small added value in predicting change in low-density lipoprotein cholesterol levels (LDL-c) as response to statins over the non-genetic predictors (P ¼ 0.104), and also in predicting LDL-c in non-treated patients (P ¼ 0.016). Moreover, four gene--gene interactions with statin therapy were identified. The added value of genetic factors over non-genetic variables is for the greater part produced by gene--gene interactions. This underlines the importance to examine gene--gene interactions in future (pharmaco)genetic research.
INTRODUCTION
Statins are widely prescribed in patients with hyperlipidemia to reduce the risk of atherosclerosis-related cardiac and vascular events, such as heart attack and stroke. Although inter-individual variability in statin response has been described for almost two decades (for example, Shear et al. 1 ), the patient characteristics that explain this variability are not completely understood. Nongenetic factors, including age, gender, race, smoking, hypertension, low-density lipoprotein (LDL) levels before treatment and waist circumference, are involved in the variation in statin response. 1--4 Also genetic factors may be partly responsible for the variability in statin response. For 440 candidate genes an association with the differential effect of statins has been described, as recently reviewed, 5 including variants in apolipoprotein E (ApoE), 6 polymorphisms in the gene encoding the cholesteryl ester transfer protein (CETP), 7, 8 the arginine-coding allele of kinesin-like protein 6 (KIF6) 9, 10 and polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene. 11 However, findings of genetic associations with statin response have not always been consistent. This may be caused by limitations of the study design, by the use of different measures to estimate statin response, including lipid levels, angiographic measurements and coronary events. Moreover, most studies examined associations of individual genetic polymorphisms with treatment response. In general, a multivariable approach rather than a single factor approach is necessary to investigate the value of prognostic markers 12 as a single predictor rarely estimates treatment response adequately. Also the effect of gene--gene interactions has not yet been thoroughly investigated in relation to statin response, although complex interactions are likely to be more important than the independent main effects of a gene, similar as proposed in the genetic architecture of common human diseases. 13 Ubiquity of gene--gene interactions could also be an explanation for non-replication of positive associations across independent samples. 13 Therefore, the current evidence is insufficient to assess the added value of pharmacogenetic testing in predicting statin response in a clinical setting, when other predictive demographic and clinical factors are readily available.
In this study, we aimed to investigate whether some of the known genetic factors, both as single-nucleotide polymorphisms (SNPs) and as gene--gene interactions, have an added value over non-genetic factors in predicting statin response.
MATERIALS AND METHODS

Study population
Data from the Regression Growth Evaluation Statin Study (REGRESS) was used, which has been described in detail elsewhere.
14 In short, REGRESS is a double-blind, placebo-controlled, multicenter study assessing the effect of 2-year pravastatin treatment on the progression and regression of coronary atherosclerosis. A total of 884 male subjects with coronary artery disease (CAD) were randomized to either pravastatin (40 mg) or placebo. Each patient had at least one coronary artery with a stenosis of 50% or more, a total cholesterol level between 4 and 8 mmol l À1 and triglycerides o4 mmol l À1 .
Pravastatin treatment response
The change in LDL-c was used to determine the response to treatment after 2 years of pravastatin treatment. The change in LDL-c was defined as the LDL-c level after 2 years of treatment with pravastatin or placebo minus the LDL-c level at baseline. Consequently, a negative outcome corresponds to a decrease in LDL-c, which is the intended drug effect. Cholesterol levels were derived from blood samples as has been described before 14 and calculated according to the Friedewald formula.
Non-genetic factors
The selection of non-genetic predictors, including demographic, clinical and lifestyle determinants, was based on factors suggested in literature to be involved in the variation in statin response, 1--4 and on availability at baseline of the trial: age, blood pressure, body mass index (BMI), smoking, total cholesterol at baseline, high-density lipoprotein cholesterol (HDL-c) at baseline and triglycerides at baseline. LDL-c at baseline was excluded from the analysis due to multicollinearity with total cholesterol. BMI was added in the models as a categorical variable: BMI p25 kg m À2 as normal, BMI 25 up to 30 kg m À2 as overweight and BMI 430 kg m À2 as obese.
Genetic factors
Genomic DNA was isolated from white cells collected at baseline via standard procedures, dissolved in 10 mmol l À1 Tris, 1 mmol l À1 EDTA, pH 8.0, and stored at 4 1C. Genotypes of the REGRESS participants for whom DNA was available were ascertained by restriction fragment length polymorphism assays using oligonucleotides and endonucleases as described previously. 15--17 Five common polymorphisms in four genes were selected, based on the criterion that they were reported and replicated in literature to influence responsiveness to statin therapy.
e2, e3 and e4 alleles in ApoE (rs429358 and rs7412). ApoE has been frequently studied in relation to statin response, especially the three common ApoE alleles e2, e3 and e4, as recently reviewed. 6 The review showed, despite some inconsistencies in findings, that carrying the e4 allele is associated with poorer response to statin treatment and carrying the e2 allele is associated with the greatest cholesterol-lowering effect, as found in, amongst others, the STRENGTH study, 18 the PROVE IT-TIMI study 19 and in the TNT cohort. 20 In our study, three different genotype groups were distinguished: ApoE3 (Apo e3e3), ApoE2 þ (Apo e2e2 or Apo e2e3) and ApoE4 þ (Apo e3e4 or Apo e4e4). The rare Apo e2e4 (n ¼ 4) was excluded from the analysis.
Insertion/deletion polymorphism in ACE (rs4646994). Carrying the deletion allele of the insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene has been associated with a beneficial statin response on different outcome measures in the LCAS population and the PREFACE study. 21, 22 Even though the association with statin response is not consistent for the I/D polymorphism, 23, 24 it was decided to include it as the association has been replicated. Three genotypes were distinguished, based on the presence of deletion allele: ACE II (ACE I/I), ACE ID (ACE I/D) and ACE DD (ACE D/D).
-154C4T polymorphism in HL (rs1800588). Findings of the À514C4T polymorphism in relation with the response of HDL-c to statin treatment are ambiguous. Zambon et al. 25 described the CC genotype showing highest response to statins on HDL, whereas the RAP study concluded that carriers of the T allele have the highest HDL-C increase. 26 However, it was decided to include this polymorphism in our analysis, as it has been described to modify the response to statin treatment more than once. As in the REGRESS data homozygous carriers of the variant allele are rare, two hepatic lipase (HL) genotype groups were created: HL-C (HL C/C) and HL-T (HL C/T or HL T/T).
Asp299Gly polymorphism in TLR4 (rs4986790). In the REGRESS study, toll-like receptor 4 (TLR4) 299Gly carriers had significantly more benefit from pravastatin treatment in preventing cardiovascular events. 27 Subsequently, in a meta-analysis including the REGRESS data, a consistent trend was shown towards reduced frequency of carriers of the variant allele with myocardial infarction in three independent studies. 28 Two genotype groups were made for TLR4, as homozygous carriers of the variant allele are rare: TLR4Asp (TLR4 Asp/Asp) and TLR4Gly (TLR4 Asp/Gly or TLR4 Gly/Gly).
Other polymorphisms for which the association with response to statin treatment has been replicated, for example, Trp719Arg in KIF6 (rs20455), 9, 10 could not be analyzed as they were not available for the REGRESS participants. The TaqIB polymorphism in the CETP gene has been associated with a different pravastatin response in delay in progression of coronary atherosclerosis 7 though a meta analysis of 13 677 subjects concluded that this CETP variant does not influence the response to pravastatin therapy, 29 so this polymorphism was not taken into account in this study.
Data analysis
Three linear regression models were built and compared with estimate the added value of SNPs and gene--gene interactions in the explanation of statin response: a model with all non-genetic variables (model 1), a model with all non-genetic variables and the single SNPs (model 2), and a model with all non-genetic variables, the single SNPs and the gene--gene interactions (model 3). In total, thirteen gene--gene interaction terms can be formed with the six genotype variables, which were all added in model 3. These three models were made for the patients randomized to pravastatin and for the patients randomized to placebo. Subsequently, the same three models were built for the overall population, including the same determinants plus the interaction of each determinant with statin treatment. This model shows which of the factors are an effect modifier for statin treatment. The R 2 , which is the percentage of the total variance of the outcome measure explained by the variables in the model, was used to indicate the performance of the models. With a F-test the R 2 of model 2 and 3 were compared with model 1 to investigate whether the addition of the genetic variables significantly improved the model. In addition, the most notable genetic variables and gene--gene interactions associated with statin response are described. For this exploratory analysis, the variables with a P-value o0.10 were considered of interest and further discussed (without correcting for multiple testing). Missing non-genetic values were imputed (single) with regression imputation, using all nongenetic variables. All analyses were performed with SPSS software (SPSS 17.0; SPSS, Chicago, IL, USA).
RESULTS
In the REGRESS trial, information on LDL-c at follow-up and genotype information on ACE, ApoE, HL and TLR4 was available for 707 subjects; 361 received pravastatin and of 346 placebo (intention-to-treat population). Table 1 shows the baseline characteristics of these patients. The mean age was 55.9 years and the more than half of the patients had a BMI between 25 and 30 kg m À2 (mean BMI was 26.1 kg m À12 ). About half of the patients had a history of previous myocardial infarction, over a quarter was hypertensive (by history) and a quarter was current smoker. By the criterion of a stenosis of X50% being considered significant, 60% of the patients had multivessel CAD. The genotype distributions of ApoE, HL and TLR4 were in Hardy--Weinberg equilibrium, in contrast to the genotype distribution of ACE (w 2 ¼ 4.3, P ¼ 0.038). Patients treated with pravastatin had a mean LDL-c change of À1.23 mmol l À1 (À27.9%) after 2 years, compared with an increase in LDL-c of 0.037 mmol l À1 (2.03%) for the placebo users. Table 2 presents the performance (R 2 ) of the models for a 2-year change in LDL-c, for the treatment group and for the placebo group separately, and for the combined model with all patients. The total percentage variance explained was higher for the statin users compared with the placebo users. The non-genetic variables (model 1) predicted 43.0% variance for the statin users and 24.4% in the placebo group. Addition of the genotypes to this model (model 2) increased the R 2 for both groups. The R 2 raised to 44.7% for the statin users and to 26.4% for the placebo group. This means that these selected polymorphisms seem to have an added value both in predicting statin response in terms of change in LDLc and in predicting LDL-c without statin use. Addition of the gene--gene interaction terms (model 3) increased the R 2 even further to 47.4% for the statin users, and to 32.1% in the placebo group. Therefore, the SNPs and gene--gene interactions seem to have a predicted value for the patients treated with statins, over the demographic, clinical and lifestyle variables in predicting change in LDL-c, although this was not a significant increase (P ¼ 0.104). In the placebo group, the genetic variables did have a significant predicted value over the non-genetic variables in predicting LDL-c change without treatment (P ¼ 0.016), showing that the genetic variables are associated with course of LDL-c in patients with CAD. A model with only the genetic variables explained 3.8% of the variance in change in LDL-c in the treatment group and 6.7% in the placebo group.
In the third column of Table 2 , the R 2 of the prognostic models for the overall population are presented. Only the variable 'treatment' predicted 50.0% of the variance, adding the nongenetic factors (model 1) raised the R 2 to 67.3%. Adding the selected polymorphisms and the gene--gene interaction terms (model 3) resulted in a significant added value (P ¼ 0.009) in predicting the change in LDL-c in the overall population over the non-genetic variables. The added value of the genetic factors is presented in Figure 1 , subdivided into the contribution of the single loci and the contribution of the gene--gene interactions. The gene--gene interactions appear to be responsible for the largest part of the explained variance by the genetic factors. Table 3 shows the complete models for patients receiving statins and placebo combined. In model 2, the effect of the selected polymorphisms without gene--gene interactions is When the gene--gene interaction terms were added (model 3), the beneficial effect of statins in combination with the ApoE2 þ genotype seemed to have disappeared (b ¼ 0.051, P ¼ 0.849). However, the positive effect on LDL-c change was still observed in patients with the ApoE2 þ genotype in combination with ACE ID (b ¼ À0.562, P ¼ 0.068). Carrying the combination of ApoE2 þ and TLR4Gly also seemed to result in a interaction with statin treatment (b ¼ À0.796, P ¼ 0.079). In the example below, the interpretation of Table 3 is illustrated for a fictive patient, carrying this combination of ApoE2 þ and TLR4Gly. The predicted difference for this patient in LDL-c levels with and without statin treatment was as much as 2.44 mmol l Table 3 The beta coefficients are the estimates of the expected change in LDL-c per increase of one unit of the predictor variable. The beta coefficient of a predictor (without interaction) is the impact of this predictor on LDL-c change without statin therapy. The impact of a predictor on LDL-c change under statin therapy is the sum of the beta coefficient of the predictor variable and the beta coefficient of the interaction term of the predictor with the statin intervention.
As an example, for a 53 year-old patient, with a BMI of 28, blood pressure 140/90, former smoker, total cholesterol is 6.26 mmol l À1 , HDL-c is 1.00 mmol l À1 , triglycerides 2.10 mmol l À1 and carrying ACE I/I, Apo e2e3, HL C/C and TLR4 Gly/Gly, treated without a statin, the predicted change in LDL-c is: 2.020À53 Â 0. 
DISCUSSION
Our study demonstrates that the 5 selected polymorphisms and the 13 corresponding gene--gene interactions have a small added value in predicting LDL-c change as response to statins over the non-genetic predictors, and also in predicting LDL-c in nontreated patients. Moreover, the gene--gene interactions appear to be responsible for the largest part of the explained variance by the genetic factors. Our combined model for statin and placebo users showed three notable interactions between single polymorphisms and statin treatment (model 2). The interaction between statin and carrying one deletion allele of the I/D polymorphism in ACE on LDL-c change has been described before, 21 however, we did not find an interaction with the D/D genotype. We identified an interaction between Apo e2 and statins, and found Apo e2 to be a predictor of better statin response in terms of LDL-c change than Apo e3, in concordance with earlier findings. 6 The interaction we described between statin and carrying a TLR4 299Gly allele on LDL-c change was also found for a lower risk of cardiovascular events as outcome for statin treatment. 28 An association with HL and statin response 25, 26 could not be replicated in our data. Removing this polymorphism from our analysis resulted in similar added value for the remaining genetic factors in terms of R 2 for both placebo and statin models and in lower P-values as less variables were added to the models (data not shown).
The combined model for statin and placebo users also showed some interesting gene--gene interactions with statin (model 3). Carrying the combination of Apo e2 and ACE I/D predicted more LDL-c decrease upon statin treatment. This interaction seems to be responsible for the association found in the single polymorphism analysis of ACE I/D (model 2) and may be worth to try and replicate in different data and with different measures for statin response. We also described three gene--gene interactions including the TLR4 299Gly allele, both with placebo and with statin. Carrying the TLR4 299Gly allele in combination with either Apo e2 or Apo e4 therefore seems to be a predictor for worse LDL-c levels in untreated patients, and statin treatment in these patients seems to compensate for this effect. For patients carrying the TLR4 299Gly allele in combination with ACE I/D, the opposite seems true: a relatively small increase in LDL-c is expected without treatment and these patients have a relatively small benefit of statin treatment.
Our results strengthen the hypothesis that gene--gene interactions are a ubiquitous component of pharmacogenetics, as also has been postulated for the genetic architecture of common human diseases. 13 To the best of our knowledge, results on epistasis have not been published in relation to statin response, though the influence of gene--gene interactions has been demonstrated on response to albuterol therapy, 30, 31 clozapine therapy 32 and warfarin therapy. 33 Our results and these examples illustrate the importance of taking these interactions into account in (pharmaco)genetic research, but as the number of polymorphisms increases, the number of gene--gene combinations challenges the traditional statistical methods. Alternative statistical tools to detect and model gene--gene interactions have been suggested, including the multifactor dimensionality reduction method. 34 The main strength of our study is that we used randomized controlled trial data, which gives the possibility to compare LDL-c levels between statin users and placebo users. Therefore, we were able to identify those genetic factors that are predictors for LDL-c in patients with and without treatment.
The ACE genotype distribution was not in Hardy--Weinberg equilibrium, representing a (small) overrepresentation of patients with a D/D genotype, which was to be expected, as the ACE D allele has been shown to increase the risk of CAD. Abbreviations: ACE, angiotensin-converting enzyme; ApoE, apolipoprotein E; BMI, body mass index; BP, blood pressure; HDL-c, high-density lipoprotein cholesterol; HL, hepatic lipase; LDL-c, low-density lipoprotein cholesterol; TLR, toll-like receptor 4; Trigl., triglycerides. Model 1 comprises of the non-genetic factors, model 2 comprises of the same non-genetic factors as model 1 plus the genotypes of ACE, ApoE, HL and TLR4, and model 3 comprises of the non-genetic factors, the genotypes and the gene--gene interaction terms. The models are developed for the overall study population, including interaction terms of each determinant with statin treatment. b is the beta coefficient, with corresponding standard error, and the P-value indicates the significance.
